Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Phase III trial of Actimmune begins for treatment of idiopathic pulmonary fibrosis

Oct. 6, 2000

New cyclic amide compounds synthesized at Japanese lab act as selective M3 antagonists

Oct. 5, 2000

Cathepsin inhibitors claimed by AstraZeneca for use in COPD

Oct. 5, 2000

FDA approves breath-activated device with corticosteroid for asthma

Oct. 5, 2000

Novel IL-5 biosynthesis inhibitor R-146225 profiled at recent inflammation meeting

Oct. 4, 2000

Inspire submits IND for new cystic fibrosis treatment

Oct. 4, 2000

Selectin inhibitor OC-229-648 chosen for further evaluation in COPD and asthma

Oct. 4, 2000

Bicyclic compounds and their use in inflammation reported in Aventis patent

Oct. 4, 2000

Dual D2/beta2-adrenoceptor agonists in clinical development at AstraZeneca for respiratory diseases

Oct. 3, 2000

Sanofi-Synthelabo presents new selective NK1 receptor antagonists

Sep. 29, 2000

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...